Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs
Piotr J. Kamola(GlaxoSmithKline (United Kingdom)), Joel D. Parry(Age UK), Kay Rush(GlaxoSmithKline (United Kingdom)), Probash Chowdhury(GlaxoSmithKline (United Kingdom)), Kenneth L. Clark(Northern Research Station), Paul A. Wilson(GlaxoSmithKline (United Kingdom)), T. Mullaney(GlaxoSmithKline (United Kingdom)), Jim Ridings(GlaxoSmithKline (United Kingdom)), Sean J. McCawley(GlaxoSmithKline (United Kingdom)), Aude Roulois(GlaxoSmithKline (United Kingdom)), Ann Fairchild(GlaxoSmithKline (United Kingdom)), Klio Maratou(GlaxoSmithKline (United Kingdom)), Tom P. McKevitt(GlaxoSmithKline (United Kingdom)), Kitty Moores(GlaxoSmithKline (United Kingdom)), Stephen Hughes(GlaxoSmithKline (United Kingdom)), Timothy W. Gant(Natural Environment Research Council), Karen Cartwright(GlaxoSmithKline (United Kingdom)), Mark R. Edbrooke(GlaxoSmithKline (United Kingdom)), Paula Evans(GlaxoSmithKline (United Kingdom)), Nigel J. Gooderham(Imperial College London)
Cited by 62
Related Papers
Characterization of the human patatin-like phospholipase family
|Journal of Lipid Research|2006|302
Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation
|PLoS ONE|2010|127
<i>In silico</i>and<i>in vitro</i>evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization
|Nucleic Acids Research|2015|109
Assessing unintended hybridization-induced biological effects of oligonucleotides
|Nature Biotechnology|2012|108
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
|Advanced Drug Delivery Reviews|2014|91